Barclays analyst Luke Sergott initiates coverage on Medpace (NASDAQ: MEDP) with a Equalweight rating and a price target of $300.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE